Italy Pharmaceutical Licensing

This guide covers only public retail pharmacies, wholesale and manufacture/import of human medicines in Italy. Placing medicines on the market, manufacturing/importing, wholesaling and distance selling are regulated separately. Medical devices, health supplements, veterinary medicines, hospital supply and non-holding brokers should not be treated as directly subject to the same requirements.

Company formation or commercial registration is distinct from pharmaceutical permissions. No general conclusion applicable to all foreign investments, foreign companies or non-Italian professionals has been verified for this guide; each project should separately verify the entity, personnel, premises, activities, AIC and cross-border supply chain.

— Retail: local pharmacy authorisation.

— Wholesale: warehouse authorisation and GDP.

— Manufacture/import: AIFA MIA, QP and GMP.

— Product/cross-border: AIC, controlled medicines and other requirements are handled separately.

AIFA is the central competent authority for manufacturing/import MIA, GMP inspections, QP qualification and medicinal product AIC. Applications and inspections for manufacturing facilities are handled through AIFA’s GMP MED system.

Wholesale authorisations are issued by the regions, autonomous provinces or authorities designated by them in accordance with law, and are valid only for the premises listed within their territory. Municipalities identify areas for new pharmacy outlets, while the local health authority handles authorisation; the actual platform and documentation vary by region.

— AIFA：MIA、GMP、QP、AIC。

— Region/autonomous province: wholesale warehouse authorisation.

— Municipality/health authority: pharmacy outlets and authorisation.

— Ministry of Health: online medicine sales, controlled substances and certain documentation procedures.

A public pharmacy is not an ordinary retail registration. The national framework uses one pharmacy for every 3,300 residents as the planning benchmark. After consulting the local health authority and pharmacists’ association, the municipality identifies areas for new outlets, taking account of balanced distribution and services in sparsely populated areas. The relevant local authority handles the specific authorisation.

A private pharmacy may be operated by an individual, partnership, capital company or limited-liability cooperative; a company pharmacy must have a pharmacist in charge who meets the statutory qualification requirements. This does not amount to a uniform ratio, not verified in this guide, for all shareholders, foreign investment or pharmacist staffing.

Online medicine sales require separate local authorisation and are limited to non-prescription medicines, SOP/OTC; wholesalers may not sell human medicines online to the public.

— New outlet: first check the municipal pharmacy plan, available positions and local filing route.

— Company pharmacy: appoint a pharmacist in charge who meets the statutory qualification requirements.

— Opening, relocation, ancillary premises and other activities: apply or notify separately under the health/municipal procedures applicable at the location.

— Online sales: obtain separate authorisation from the region/autonomous province or its designated authority, and complete the Ministry of Health listing procedure.

Wholesale is the activity of procuring, holding, supplying or exporting medicines without supplying them to the public, and requires local wholesale authorisation. Authorisation applies to a specific warehouse; separate applications are required for multiple warehouses in different regions. A manufacturing MIA may exempt the holder from obtaining separate wholesale authorisation only for medicines/active substances for which wholesale is covered by the MIA itself.

The applicant must have suitable premises, equipment and personnel, and a responsible person who performs their duties on an ongoing basis at the authorised location. In general, the responsible person must hold a degree in pharmacy, chemistry, pharmaceutical chemistry and technology, or industrial chemistry; the exception for medical gases should not be generalised.

A wholesale authorisation is subject to a prior warehouse inspection and must specify the warehouse, responsible person, authorised medicines/categories and service area. The competent authority must notify the outcome within 90 days of the application; requests for additional documents suspend the period, so this is not a guaranteed actual approval timeframe.

— Confirm whether the activity is full wholesale, contract storage, limited wholesale covered by an MIA, or brokering without holding stock.

— Prepare authorisation and inspection materials for each warehouse and each local authority.

— Appoint a responsible person who performs their duties on an ongoing basis, and ensure the GDP quality system covers supply, storage and transport, and customer eligibility.

— Assess separately any additional Ministry of Health or other permits for controlled drugs and special categories.

Manufacturing medicines in Italy, even solely for export, requires prior AIFA authorisation. The application must specify the medicine/dosage form and manufacturing and control sites, and demonstrate the premises, equipment, control and storage capabilities, as well as at least one QP; AIFA decides following a direct inspection.

AIFA GMP MED handles new manufacturing/import facilities, major/minor changes, import extensions and investigational medicinal products separately. An MIA specifies the authorised scope of manufacture, packaging, quality control, batch certification and import; additional special categories or scope must not be presumed to be covered by an existing MIA.

A manufacturing authorisation does not replace product AIC. Imports from third countries are generally subject to manufacturing/import rules; statutory exceptions may apply where EU mutual-recognition arrangements are applicable.

— Define the scope of the MIA application by product, dosage form, process, manufacturing/control site and import chain.

— Prepare GMP premises, equipment, quality control, storage, technical documentation and QP arrangements.

— Apply for a new facility, import or authorisation change using the forms specified by AIFA GMP MED.

— Separately complete product AIC, labelling, batch release and cross-border/controlled-product requirements.

The professional roles differ across the three business lines: a company pharmacy is managed by a pharmacist who meets the statutory qualification requirements; a wholesale warehouse has a responsible person who performs their duties on an ongoing basis; and a manufacturing/import authorisation holder must have at least one AIFA-recognised QP. These roles must not be conflated.

The QP must maintain an ongoing relationship with the company. The law sets out relevant degrees, practical experience, professional qualifications and register requirements; practical experience generally consists of at least two years of quality analysis, testing and verification at an authorised manufacturing company. Statutory exceptions must be assessed on a case-by-case basis.

Foreign qualifications, professional/practice qualifications, recognition of translations and actual employment arrangements are not fully covered by the public materials reviewed for this guide. Do not assert that a foreign degree, group position or shareholder status qualifies someone to hold a statutory position in Italy.

— Pharmacy: verify the pharmacist in charge’s qualification and local requirements.

— Wholesale: verify the responsible person’s degree, ongoing presence arrangements and suitability for the authorised warehouse.

— Manufacturing: verify with AIFA the QP’s qualification, appointment/replacement and batch responsibilities.

Retail pharmacy premises are subject first to pharmacy outlet planning and local authorisation requirements. National rules state that municipalities should identify areas according to balanced distribution and accessibility of services, but this review did not verify a uniform minimum area or fit-out template applicable to all pharmacies throughout Italy.

Wholesale distribution requires premises, installations and equipment capable of ensuring proper storage and distribution. GDP covers the quality system, storage and transport, traceability, anti-counterfeiting, recalls, and verification of suppliers’ and customers’ legal qualifications.

Manufacturing/importation requires production, control and storage conditions appropriate to the declared scope, and is subject to AIFA inspections. Inspection technical documentation covers the organisational structure, layout/flows, equipment, validation, SOPs, products and systems.

— Retail: the outlet/location must correspond to the pharmacy authorisation procedure in the relevant locality.

— Wholesale: the warehouse, installations, equipment, temperature control/transport and GDP quality system must correspond to the authorised scope.

— Manufacturing: the GMP layout, equipment, validation, quality control and storage must correspond to the MIA scope.

The application sequence should be determined by the actual activity. For retail projects, first verify the eligible pharmacy outlet, applicant entity and local authorisation channel; wholesale projects should apply to the authority where the warehouse is located and undergo inspection; manufacturing/importation projects should submit separate applications under the AIFA GMP MED forms for a new establishment, importation or variation. General company documents may form part of the application, but cannot replace professional authorisation.

The wholesale service page of the Autonomous Province of Bolzano is a local example only: a new establishment or warehouse relocation may require a prior health review, compliance of the intended use, floor plans, installation compliance, a responsible person’s declaration, a technical report and a product/temperature-control list; other areas must follow their current local requirements.

For a new manufacturing establishment, use AIFA Mod.031/02 and attach the specified documents; importation extensions, authorisation variations and QP appointments follow different procedures.

— 1. Determine the actual activity: retail to the public, wholesale warehousing or manufacturing/importation.

— 2. Verify that the company documents, key personnel, premises and product list are consistent with one another.

— 3. Submit the correct category of application to the local authority or AIFA and cooperate with inspections.

— 4. After authorisation, address AIC, online sales, importation, controlled drugs and registration/updates in the central database.

Manufacturing MIA: AIFA must decide within 90 days of receiving an application demonstrating compliance with the statutory conditions; requests for additional documents or corrective action suspend the time limit. Wholesale: the competent authority must notify the outcome within 90 days of the application; requests for additional documents suspend the time limit, and authorisation is conditional on prior inspection of the warehouse. Neither period is a guaranteed actual opening date.

For a significant variation to a manufacturing authorisation, AIFA’s statutory processing period is 30 days and may be extended to 90 days in special circumstances. A product AIC is usually valid for five years and may be renewed under the applicable rules, but this product term should not be applied to pharmacy, wholesale or MIA authorisations.

AIFA indicates that MIA service fees should be checked against the Ministry of Health fee decree and the specific payment information; this review did not verify a single safely citable amount covering all pharmacies, wholesale authorisations in every region and all MIAs nationwide. The two €16 stamp duties in Bolzano are a local example only.

— Verified: MIA and wholesale authorisations both have a statutory 90-day processing framework; requests for additional documents suspend the time limit.

— Verified: significant manufacturing variations take 30 days, extendable to 90 days in special circumstances.

— Verified: the five-year AIC rule applies to product authorisations, not to business premises authorisations.

— No claim made: uniform national total fees for retail/wholesale/MIA, actual opening timelines, a uniform validity period or automatic renewal.

Swipe horizontally to view all items

Wholesale authorisation holders must allow inspections; purchase and supply only within the legal supply chain; establish an emergency recall plan; retain transaction and batch records for five years; maintain transport and storage conditions; and operate quality and risk management systems.

Manufacturing authorisation holders must comply with GMP; the QP performs batch, documentation, irregularity-reporting, inspection-cooperation and health-supervision duties. AIFA’s periodic GMP inspections take place at intervals not exceeding three years; there may also be start-up, extension, follow-up, product-specific or control inspections.

Ongoing obligations for retail pharmacies are affected by the rota, responsible person, services and local reporting mechanisms in the place of authorisation; this review did not verify a nationally uniform “licence renewal date”.

— Wholesale: GDP, self-inspections, five-year record retention, qualified supply chain, transport, recalls and inspection readiness.

— Manufacturing: GMP, QP batch/documentation responsibilities, CAPA and readiness for AIFA inspections.

— Retail: maintain the local pharmacy authorisation conditions, responsible person and local service/reporting obligations.

Significant variations to the conditions of a manufacturing MIA must be submitted to AIFA; non-significant variations must be communicated under the specified procedure. The appointment, replacement or addition of a QP requires AIFA authorisation; a replacement made at short notice may perform the role before a formal decision only if notification is timely and the supporting evidence is adequate. AIFA also lists procedures for administrative changes, such as changes to the company or site.

There is a Ministry of Health update route for wholesale information in the central database, including the name, registered legal address, name of the entity/logistics location and contact details; a copy of the local authorisation must be uploaded. This does not replace the assessment of whether changes involving the warehouse, scope or responsible person require a local authorisation variation.

The operating rights of a private pharmacy may generally be transferred only after three years from the granting of the operating authorisation; statutory exceptions, including inheritance, are subject to separate rules. This does not mean that a share transaction, asset transaction or change of address automatically continues the pharmacy licence.

— Manufacturing: first determine whether the variation is significant or non-significant, then use the corresponding AIFA module; QP changes require special handling.

— Wholesale: confirm changes to authorisation details with the original local authority and also complete applicable updates to the Ministry of Health central database.

— Retail: Before a transaction, relocation or management change, confirm with the competent pharmacy authority in the relevant location whether a new authorisation, consent or notification is required.

After a pharmacy, wholesale or manufacturing premises has obtained authorisation, each individual medicinal product must still have an applicable product-level AIC before it may be placed on the market in Italy; an AIC is obtained from AIFA or through a Community authorisation under EU rules. AIFA lists different routes, including national, mutual-recognition/decentralised and centralised procedures, as well as parallel imports.

Imports of medicinal products from third countries generally fall under the manufacturing/import authorisation and QP/GMP framework. Product-level AIC, MIA for the importing/manufacturing site, wholesale authorisation, quality release, and labelling/unique identifiers each serve a distinct function and do not automatically cover one another.

Import, export and transit permits for narcotic and psychotropic substances are handled through the Ministry of Health’s electronic procedure; a general pharmacy, wholesale or MIA authorisation cannot replace such a permit.

— For each SKU: verify the AIC/applicable EU route, product status and authorisation holder.

— Imports from third countries: verify the MIA, QP, GMP, batch release and any mutual-recognition exceptions.

— Cross-border activity within the EU, parallel imports or distribution: assess each case under the rules applicable to the product, entity and notification.

— Narcotic drugs, psychotropic substances and other controlled products: obtain a separate Ministry of Health permit; do not infer this from a general business authorisation.